News explainer

HLP003 Phase 3 Results

HLP003 is not FDA-approved, and Helus Pharma reported three unnamed treatment-related serious adverse events in the APPROACH trial.

HLP003 Is Not FDA-Approved

HLP003 is investigational and is not approved by the Food and Drug Administration (FDA). In a November 16, 2026 announcement, Helus Pharma called the Phase 3 APPROACH results positive. Helus Pharma reported three HLP003 treatment-related serious adverse events (SAEs) but did not name the events.

APPROACH studied HLP003 alongside existing antidepressant medication in adults with major depressive disorder (MDD). Helus Pharma says HLP003 has FDA Breakthrough Therapy designation. That designation concerns drug development and review. It does not approve HLP003 for use.

A New Drug Application (NDA) submission, FDA acceptance of a filing and an FDA decision for HLP003 are not reported in the sources reviewed as of November 16, 2026. Helus Pharma expects results from another pivotal study, EMBRACE, in the fourth quarter of 2027, while warning that the timeline may change. The reported APPROACH results do not establish an FDA decision date.

HLP003 APPROACH Efficacy Results

Helus Pharma reports a larger drop in depression scores with HLP003 than with placebo at Week 6 of the APPROACH trial. The least squares (LS) mean difference on the Montgomery-Asberg Depression Rating Scale (MADRS) was -7.6 points (p<0.0001). These are topline figures from a Helus Pharma press release and have not been peer reviewed.

Helus Pharma says the trial was randomized, double-blind and placebo-controlled, and enrolled 222 adults with moderate to severe major depressive disorder (MDD) who kept taking a stable antidepressant dose. The MADRS rows below show the average reduction in total score from baseline, so a larger number means a larger drop in rated symptoms. Response means a reduction of at least 50% from baseline, and remission means a MADRS total score of 10 or lower.

Measure reported by Helus PharmaHLP003PlaceboDifference or p-value
MADRS reduction at Day 216.1 points11.0 points-5.0 points (p=0.0013)
MADRS reduction at Week 6 (primary endpoint)19.5 points11.9 points-7.6 points (p<0.0001)
MADRS reduction at Week 12 (key secondary endpoint)16.9 points9.9 points-7.0 points (p<0.0001)
Response rate at Day 250.0%23.6%p=0.0002
Response rate at Week 656.3%28.2%p<0.0001
Response rate at Week 1245.5%19.1%p<0.0001
Remission rate at Day 239.3%15.5%p=0.0002
Remission rate at Week 650.9%18.2%p<0.0001
Remission rate at Week 1240.2%15.5%p<0.0001

Source: Helus Pharma release, November 16, 2026. The release lists 112 participants in the HLP003 group and 110 in the placebo group for the response and remission rows. Helus Pharma also reports Clinical Global Impression Scale improvements over placebo starting at Day 2 but gives no figures for them.

HLP003 is not yet an approved depression treatment. It is investigational, and the FDA has not approved it. APPROACH is one of two pivotal studies, and Helus Pharma expects topline results from the second, EMBRACE, in the fourth quarter of 2027. The release also says the FDA and Health Canada have not evaluated claims about HLP003.

The release reports three HLP003 treatment-related serious adverse events and gives no placebo-group count or event details, so a reader cannot compare serious events between the groups. Helus Pharma disclosed only a count of serious events (see The Three Treatment-Related Serious Adverse Events). The figures above are the sponsor's and do not show that HLP003 treats depression.

HLP003 Phase 3 Results at a Glance

The November 16 announcement establishes an APPROACH topline readout and describes studies that remain underway. The regulatory milestones below distinguish Helus Pharma's stated plans from an application or decision by the FDA.

"Not reported in the sources reviewed" describes the limits of the material checked and does not establish that no filing or other regulatory event exists elsewhere.

MilestoneStatus as of November 16, 2026Source and date
APPROACH toplineHelus Pharma announced what it calls positive Phase 3 results for adjunctive treatment of MDD and reports a Week 6 MADRS difference of -7.6 points versus placebo (p<0.0001). The figures are sponsor-reported and not peer reviewed.Helus Pharma release, November 16, 2026
Breakthrough Therapy designationHelus Pharma says HLP003 holds the designation. It is not an FDA approval.Helus Pharma release, November 16, 2026, and FDA Breakthrough Therapy page
NDA submissionNot reported in the sources reviewed.Helus Pharma release, November 16, 2026
FDA acceptance of a filingNot reported in the sources reviewed.Helus Pharma release, November 16, 2026
FDA decisionNot reported in the sources reviewed. HLP003 is not FDA-approved.Helus Pharma release, November 16, 2026, and FDA Breakthrough Therapy page
EMBRACE toplineExpected in the fourth quarter of 2027, according to Helus Pharma. Helus Pharma says there is no assurance the timeline will be met.Helus Pharma release, November 16, 2026
EXTEND studyOngoing long-term extension study intended to provide more safety and durability data.Helus Pharma release, November 16, 2026

What the APPROACH Trial Was

APPROACH was Helus Pharma's randomized, double-blind, placebo-controlled Phase 3 study of HLP003 as an add-on to antidepressant medication. The intent-to-treat population included 222 adults with moderate to severe MDD. Participants continued their stable antidepressant doses throughout the study.

The results table in Helus Pharma's release lists 112 participants in the HLP003 group and 110 in the placebo group. Trial entry required a confirmed MDD diagnosis and a Montgomery-Asberg Depression Rating Scale (MADRS) total score of at least 24 at screening and baseline. The announcement does not say that an inadequate response to an earlier antidepressant was an enrollment requirement.

Studies of treatment-resistant depression enrol a different population, so APPROACH cannot be compared with them directly. APPROACH assessed HLP003 added to stable medication in the population described by Helus Pharma. It did not test a switch away from that medication. For context on psilocybin trial evidence and its limits, see the psilocybin clinical trials guide.

Helus Pharma describes APPROACH as the first of three studies in its PARADIGM Phase 3 program. EMBRACE is the ongoing second pivotal study. Participants from APPROACH and EMBRACE may enter EXTEND, the ongoing long-term extension study intended to add safety and durability information.

Helus Pharma disclosed a count of three HLP003 treatment-related serious adverse events without describing what happened in those cases. Its safety statement reads: "HLP003 was generally well tolerated in the APPROACH study. Most adverse events were mild to moderate in severity, transient, and primarily limited to the day of dosing. There were three HLP003 treatment-related serious adverse events in the study. No new safety signals were identified."

The announcement does not name the three serious events, give their timing or report their outcomes. It also does not give the placebo group's serious-adverse-event count or a study-wide total from all causes. Those missing details prevent a reader from determining what the three events involved or comparing serious events across the trial groups.

STAT's post on X says Helus Pharma faces safety questions with "a number of serious adverse events reported." Helus Pharma's count is specifically for HLP003 treatment-related serious adverse events. The sources reviewed do not establish whether STAT's wording refers to those same events, includes other events or includes the placebo group.

Reuters Legal's post on X reports Helus Pharma's announcement of Phase 3 results but gives no serious-adverse-event details. Only the text of the STAT and Reuters Legal posts was reviewed. Their linked articles were not reviewed. Panabee's November 16 account likewise notes that the topline disclosure does not show what the events involved.

The statements cannot be reconciled from the sources reviewed, and the total number of serious adverse events is not reported there. Event names, timing, outcomes and arm-by-arm totals would allow a more specific account of APPROACH safety. Until those details are disclosed, Helus Pharma's "no new safety signals" statement remains its characterization of the topline data.

What Happens Next at the FDA for HLP003

HLP003's Breakthrough Therapy designation does not replace an FDA filing or approval decision. The FDA's Breakthrough Therapy page describes a process intended to expedite development and review when preliminary clinical evidence indicates a drug may substantially improve on available therapy for a serious condition. The designation can bring intensive FDA guidance during development.

Helus Pharma reports no NDA submission date or filing timeline for HLP003 in its November 16 release. FDA acceptance of an HLP003 filing and an FDA decision are also not reported in the sources reviewed. Breakthrough Therapy designation alone cannot supply any of those missing milestones.

The next stated study milestone is the EMBRACE topline, which Helus Pharma expects in the fourth quarter of 2027. Helus Pharma explicitly says there is no assurance that timeline will be met. EXTEND remains ongoing and is intended to add longer-term safety and durability data. The announcement does not turn either study timeline into an FDA decision date.

Another investigational program's milestones are described in Definium's DT120 review timeline. That separate program cannot establish when Helus Pharma might submit HLP003 or when the FDA might act on it. An HLP003-specific filing announcement would provide a firmer next regulatory milestone.

How HLP003 Differs from COMP360

HLP003 and COMP360 concern different molecules, depression study populations and regulatory stages. Compass Pathways completed an NDA submission for COMP360 on November 9, 2026, according to The Psychedelic Journal's COMP360 FDA status explainer. An HLP003 NDA submission is not reported in the sources reviewed as of November 16, 2026.

AttributeHLP003 (Helus Pharma)COMP360 (Compass Pathways)
Molecule as describedDeuterated psilocin.Investigational synthetic, proprietary formulation of psilocybin.
SponsorHelus Pharma.Compass Pathways.
Program indicationPotential adjunctive treatment of major depressive disorder.Treatment-resistant depression.
Population in the reported trialsAPPROACH enrolled adults with moderate to severe major depressive disorder who continued stable antidepressant medication.Compass Pathways describes data from participants with chronic treatment-resistant depression, defined in its release by an inadequate response to at least two adequate antidepressant courses.
Regulatory stagePhase 3 APPROACH topline announced. Second pivotal study EMBRACE ongoing.NDA submission completed November 9, 2026. FDA acceptance and a decision were not reported in sources checked November 12.
Breakthrough Therapy designationHelus Pharma says HLP003 holds FDA designation.Compass Pathways says COMP360 holds FDA designation.
NDA statusSubmission not reported in the sources reviewed as of November 16, 2026.Submission completed November 9, 2026, according to Compass Pathways.

APPROACH studied an add-on treatment in participants taking stable antidepressants. Compass Pathways' reported COMP360 studies concern treatment-resistant depression, a different enrollment frame. These trials are not matched, so their results cannot establish which candidate is safer or more effective.

The completed COMP360 NDA is a filing milestone. It is not an FDA approval of COMP360. The distinction also prevents COMP360's reported launch expectations from serving as an availability estimate for HLP003. FDA acceptance and an FDA decision for COMP360 were not reported in the sources reviewed for the COMP360 explainer on November 12, 2026.

HLP003 is not FDA-approved. The sources reviewed describe it only as an investigational drug under study, and they report no controlled-substance status for HLP003, so no HLP003 scheduling claim is made here.

Federal regulation lists psilocyn, the regulatory spelling of psilocin, in Schedule I at 21 CFR 1308.11(d)(30). Helus Pharma describes HLP003 as deuterated psilocin, but that listing does not establish how HLP003 itself is scheduled.

For the federal listing of psilocin itself, read is psilocin legal. The state legal-status tracker provides separate state-law context. Neither resource establishes the legal status of HLP003 merely by describing psilocin or state rules.

Takeaway on HLP003 Phase 3 Results and Safety Disclosure

Helus Pharma reports a Week 6 MADRS difference of -7.6 points versus placebo (p<0.0001) in 222 adults taking a stable antidepressant. That figure comes from a sponsor topline press release that has not been peer reviewed, and it covers one of two pivotal studies. Helus Pharma also reports three HLP003 treatment-related serious adverse events with no placebo-group count or event details.

Helus Pharma's positive APPROACH topline announcement does not establish that HLP003 is safe, available or FDA-approved. Helus Pharma disclosed three HLP003 treatment-related serious adverse events without naming them. STAT's post raises a broader safety question, but its wording cannot be reconciled with the count in Helus Pharma's release from the post text alone. Reuters Legal's post adds no event details.

For readers tracking the FDA pipeline, HLP003 remains an investigational Phase 3 candidate with Breakthrough Therapy designation and no NDA reported in the sources reviewed. Psilocyn's Schedule I listing does not settle how HLP003 itself is scheduled. COMP360 has reached the distinct milestone of a completed NDA submission. This comparison is about program status and is not a basis for choosing a treatment.

Peer-reviewed full APPROACH results, event-level safety disclosure, an HLP003 NDA submission or FDA filing acceptance, and EMBRACE results would change what can be said about HLP003's evidence and regulatory progress. For the latest source-backed HLP003 phase 3 results, read Helus Pharma's APPROACH announcement.

Frequently Asked Questions

Is HLP003 FDA-approved?

No. HLP003 is investigational, and an FDA approval is not reported in the sources reviewed as of November 16, 2026. Helus Pharma says HLP003 holds Breakthrough Therapy designation, which concerns development and review rather than approval.

Is HLP003 safe?

The available topline disclosure cannot settle that question. Helus Pharma reported three HLP003 treatment-related serious adverse events and said it identified no new safety signals, but it did not name the events or report their outcomes. HLP003 is not FDA-approved.

When will HLP003 be available?

No HLP003 filing, approval or launch date is reported in the sources reviewed, so no availability estimate exists in the sources reviewed. Helus Pharma expects EMBRACE topline results in the fourth quarter of 2027 but warns that the study timeline may change.

How is HLP003 different from COMP360?

Helus Pharma labels HLP003 deuterated psilocin and is studying it as an add-on treatment for major depressive disorder. Compass Pathways describes COMP360 as a psilocybin formulation for treatment-resistant depression and completed an NDA submission on November 9, 2026. The trials are not matched, so the stage gap says nothing about safety or efficacy.

What is deuterated psilocin?

"Deuterated psilocin" is how Helus Pharma describes HLP003. The sources reviewed do not provide a chemistry or pharmacology explanation beyond that label.

What is the difference between HLP003 and HLP004?

Helus Pharma describes HLP003 as its Phase 3 program for potential adjunctive treatment of major depressive disorder. It describes HLP004 as a Phase 2 program for generalized anxiety disorder. The November 16 APPROACH results concern HLP003.

Does HLP003 work?

Helus Pharma reports a larger drop in depression scores with HLP003 than with placebo at Week 6 of its APPROACH trial, a Montgomery-Asberg Depression Rating Scale difference of -7.6 points (p<0.0001) in 222 adults taking a stable antidepressant. That is a sponsor-reported topline figure from one of two pivotal studies that has not been peer reviewed. Helus Pharma also reports three HLP003 treatment-related serious adverse events with no placebo-group count. HLP003 is not FDA-approved, and its release says the FDA and Health Canada have not evaluated claims about HLP003.

Is HLP003 legal?

HLP003 is not FDA-approved, and the sources reviewed describe it only as an investigational drug under study. Federal regulation lists psilocyn, the regulatory spelling of psilocin, in Schedule I at 21 CFR 1308.11(d)(30), but that listing does not establish how HLP003 itself is scheduled, and no controlled-substance status for HLP003 is reported in the sources reviewed.

Get psychedelic research & policy updates

New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.

Free. No spam. Unsubscribe anytime.

← Back to all therapy guides

Sources

  1. Helus Pharma Inc.. Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder. GlobeNewswire news release, 16 Nov 2026, 2026. GlobeNewswire.
  2. STAT. Post on X about Helus Pharma and serious adverse events (post text only; linked article not reviewed). X, 16 Nov 2026, 2026. STAT on X.
  3. Reuters Legal. Post on X about Helus Pharma's Phase 3 announcement (post text only; linked article not reviewed). X, 16 Nov 2026, 2026. Reuters Legal on X.
  4. U.S. Food and Drug Administration. Breakthrough Therapy. FDA, For Patients (page marked current as of 01/04/2018), 2018. FDA.gov.
  5. Office of the Federal Register. 21 CFR 1308.11, Schedule I (Electronic Code of Federal Regulations). eCFR, Title 21, Chapter II, Part 1308, Subpart B (retrieved 17 Nov 2026), 2026. eCFR.
  6. Panabee. News analysis of Helus Pharma's HLP003 Phase 3 announcement, 16 Nov 2026. Panabee, 2026. Panabee.